Holen Sie sich die Stockscreener-App
20.40
1.50%
-0.30
Schlusskurs vom Vortag:
$20.70
Offen:
$20.91
24-Stunden-Volumen:
443.74K
Relative Volume:
0.27
Marktkapitalisierung:
$3.23B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-7.1579
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
+3.56%
1M Leistung:
+8.63%
6M Leistung:
+43.69%
1J Leistung:
+36.94%
1-Tages-Spanne:
$20.08
$21.42
1-Wochen-Bereich:
$20.00
$21.82
52-Wochen-Spanne:
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.37 | 3.28B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.38 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.33 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock? - Bitget
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock? - TradingView
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration - Sahm
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date - Citeline News & Insights
DNLI: Awaiting FDA decision on a novel Hunter syndrome therapy, with broad pipeline and commercial momentum - TradingView
Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1%Should You Buy? - MarketBeat
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
How Denali Therapeutics Inc. stock reacts to global recession fearsPortfolio Risk Report & Stock Market Timing Techniques - Naître et grandir
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - MSN
(DNLI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Denali Therapeutics (DNLI) Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed? - simplywall.st
HC Wainwright Issues Positive Forecast for DNLI Earnings - MarketBeat
Rafferty Asset Management LLC Buys 60,624 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Market Wrap: Can Denali Therapeutics Inc scale operations efficientlyJuly 2025 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
Bank of America Securities Remains a Buy on Denali Therapeutics (DNLI) - The Globe and Mail
DNLI: Pivotal 2026 ahead with FDA review, new launches, and major clinical milestones in rare diseases - TradingView
TD Asset Management Inc Trims Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Fisher Asset Management LLC Increases Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Wider Losses And New Shelf Registration - Sahm
Denali Therapeutics Inc. (DNLI) Investor Outlook: Analyzing The 56.80% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 182,183 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Jefferies reiterates Denali stock Buy rating on gene therapy outlook By Investing.com - Investing.com Canada
Jefferies reiterates Denali stock Buy rating on gene therapy outlook - Investing.com India
BTIG Research Increases Denali Therapeutics (NASDAQ:DNLI) Price Target to $36.00 - MarketBeat
Denali Therapeutics (DNLI): BTIG Raises Price Target to $36.00 | - GuruFocus
Denali Therapeutics Inc. Trade Ideas — GETTEX:4DN - TradingView
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - National Today
Does Denali Therapeutics' (DNLI) Widening Quarterly Loss Reframe Its Pipeline-First Investment Narrative? - simplywall.st
Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Denali Therapeutics Q4 net loss deepens - TradingView
Denali Therapeutics (DNLI) widens 2025 loss but fortifies cash for key 2026 drug milestones - Stock Titan
BRIEF-Denali Therapeutics Q4 Operating Expenses USD 137.365 Million - TradingView
Hunter syndrome drug nears April FDA call as Denali raises $475M - Stock Titan
Volume Recap: Is Denali Therapeutics Inc. a turnaround storyMarket Weekly Review & Weekly Chart Analysis and Guides - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Strong Buy Ratings Signal a 57% Potential Upside - DirectorsTalk Interviews
Wolfe Research initiates Denali Therapeutics stock with Peerperform - Investing.com
Wolfe Research initiates Denali Therapeutics stock with Peerperform By Investing.com - Investing.com UK
Wolfe Research Initiates Coverage of Denali Therapeutics (DNLI) with Peer Perform Recommendation - Nasdaq
(DNLI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Buyout Rumor: Is Denali Therapeutics Inc forming a bullish divergenceJuly 2025 Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Aberdeen Group plc Buys 210,835 Shares of Denali Therapeutics Inc. $DNLI - Defense World
Denali Therapeutics (DNLI) Expected to Announce Earnings on Thursday - MarketBeat
Denali Therapeutics Inc. $DNLI Shares Sold by Thrivent Financial for Lutherans - Defense World
Pharma could be on the cusp of finally breaking the blood-brain barrier - Pharma Voice
Big Picture: Why is Denali Therapeutics Inc stock going downJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
How Denali Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - mfd.ru
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
(DNLI) Risk Channels and Responsive Allocation - Stock Traders Daily
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):